Recombinant humanized monoclonal antibodies and VEGFR/EGFR tyrosine kinase inhibitors (TKIs) have been widely applied in the treatment of metastatic colorectal cancer, glioblastoma, as well as non-small-cell lung cancer [37]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.